Top Markets
Coin of the day
Aziyo Biologics, Inc. Aziyo Biologics, Inc.

Aziyo Biologics, Inc.

AZYO
Rank in Stocks #29677
Aziyo Biologics, Inc. (AZYO) operates as a regenerative medicine firm,... Aziyo Biologics, Inc. (AZYO) operates as a regenerative medicine firm, concentrating its efforts on developing advanced medical products. Their primary applications target three key areas: implantable electronic devices and cardiovascular care, orthopedic and spinal repair, and the reconstruction of soft tissues. The company's product portfolio includes CanGaroo, an innovative envelope that incorporates antibiotics, specifically engineered to lower the risk of infection following the surgical implantation of an electronic device. Aziyo also provides a suite of cardiovascular solutions. ProxiCor serves as an intracardiac patch or pledget for repairing heart tissues, while Tyke is designed for neonates and infants to mend pericardial structures. Additionally, VasCure offers a versatile patching material for the repair or reconstruction of peripheral blood vessels, encompassing critical arteries like the carotid, renal, iliac, femoral, and tibial, serving cardiovascular, vascular, and general surgeons. For orthopedic procedures, Aziyo offers human tissue-derived bone allografts such as Fiber VBM, ViBone, and OsteGro V. These products are formulated to protect and preserve the body's natural bone cells. In the realm of soft tissue repair, they feature SimpliDerm, a pre-hydrated human acellular dermal matrix (HADM) developed for the repair or replacement of damaged or insufficient skin and related integumental tissues. Beyond its proprietary product line, Aziyo Biologics extends contract manufacturing services, producing various items for other corporate clients. The company distributes its products to hospitals and other healthcare facilities through a multi-faceted sales approach, utilizing its dedicated direct sales force, strategic commercial partners, and independent sales agents. Founded in 2015, Aziyo Biologics, Inc. maintains its headquarters in Silver Spring, Maryland.
Share Price
$1.39
Last synced: 2023-10-03
Market Cap
$20.11M
Change (1 day)
-3.47%
Change (1 year)
0.00%
Country
US
Trade Aziyo Biologics, Inc. (AZYO)

Category

Revenue for Aziyo Biologics, Inc. (AZYO)
Revenue in Aug 2026 TTM: 0
According to Aziyo Biologics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Aziyo Biologics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$46.59B -
US
$25.84B -
US
$35.48B -
IE
$21.00B -
US
- -
DE